Why is this medication prescribed?

Trogarzo (ibalizumab-uiyk) is a prescription medication used to treat HIV (human immunodeficiency virus) infection in adults who have previously received HIV medications and have demonstrated multidrug resistance to other HIV medications. It is specifically indicated for individuals with multidrug-resistant HIV-1 infection who have failed on multiple HIV treatment regimens.

Trogarzo works by binding to the CD4 receptor on the surface of immune cells, blocking the entry of HIV into these cells. This prevents the virus from infecting and replicating within the cells, helping to reduce the viral load in the body and slow down the progression of HIV infection.

How should this medicine be used?

Trogarzo (ibalizumab-uiyk) is administered intravenously (IV) under the supervision of a healthcare professional. Here are the general steps for using Trogarzo:

• Administration Setting: Trogarzo should be administered in a clinical setting, such as a hospital infusion center or an outpatient clinic equipped to handle IV medications.
• Preparation: Before administering Trogarzo, the healthcare provider will prepare the medication according to the manufacturer’s instructions. This may involve diluting the medication solution to the appropriate concentration for IV infusion.
• Patient Preparation: The patient will be positioned comfortably for the IV infusion, typically in a chair or reclining bed.
• IV Infusion: The healthcare provider will start the IV line, usually in a vein in the arm or hand. The prepared Trogarzo solution will then be infused into the bloodstream over a period of approximately 60 minutes. The infusion rate may be adjusted based on the patient’s tolerance and any potential adverse reactions.
• Monitoring: Throughout the infusion, the healthcare provider will closely monitor the patient for any signs of adverse reactions or complications. Vital signs such as blood pressure, heart rate, and oxygen saturation may be monitored regularly.
• Post-Infusion Care: After the infusion is complete, the IV line will be removed, and the patient will be observed for a short period to ensure there are no immediate adverse effects. The healthcare provider may provide instructions for any additional post-infusion care or monitoring that may be necessary.
• Follow-Up: Patients receiving Trogarzo will typically require ongoing IV infusions every 14 days as part of their treatment regimen. They should attend all scheduled appointments for IV infusion and follow their healthcare provider’s instructions carefully.

It’s important for patients to communicate openly with their healthcare provider about any concerns or side effects they may experience during or after Trogarzo administration. Adhering to the prescribed treatment regimen and attending regular follow-up appointments is essential for effectively managing HIV infection with Trogarzo therapy.

Other uses for this medicine

• Trogarzo is primarily indicated for the treatment of HIV infection in adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
• There are no other approved uses for Trogarzo as of last update. It is specifically designed and approved for the treatment of HIV in certain cases.

What special precautions should I follow?

When using Trogarzo, it’s essential to follow certain special precautions to ensure its safe and effective use:

• Administration: Trogarzo should only be administered by a healthcare professional in a clinical setting equipped to handle IV medications. It should not be self-administered or administered by individuals without proper training and expertise.
• Monitoring: Patients receiving Trogarzo should be closely monitored for any signs of adverse reactions or complications during and after infusion. Vital signs, including blood pressure, heart rate, and oxygen saturation, may be monitored regularly.
• Adverse Reactions: Patients should be aware of potential adverse reactions associated with Trogarzo, such as hypersensitivity reactions, diarrhea, dizziness, rash, and nausea. They should promptly report any unusual symptoms or side effects to their healthcare provider.
• Drug Interactions: Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking, as Trogarzo may interact with certain medications. Potential drug interactions should be carefully monitored, and dosage adjustments may be necessary.
• Pregnancy and Breastfeeding: The safety of Trogarzo in pregnant or breastfeeding individuals has not been established. Patients should inform their healthcare provider if they are pregnant, planning to become pregnant, or breastfeeding before receiving Trogarzo.
• Immune Reconstitution Inflammatory Syndrome (IRIS): Patients with advanced HIV infection may develop IRIS after starting antiretroviral therapy, including Trogarzo. Healthcare providers should be vigilant for signs and symptoms of IRIS and manage it appropriately if it occurs.
• Compliance: Patients should adhere to the prescribed treatment regimen for Trogarzo, attending all scheduled appointments for IV infusion and following their healthcare provider’s instructions carefully.

By following these special precautions, patients can maximize the benefits of Trogarzo therapy while minimizing the risk of adverse effects or complications. It’s essential to maintain open communication with healthcare providers and seek prompt medical attention for any concerns or issues related to Trogarzo treatment.

What special dietary instructions should I follow?

There are no specific dietary restrictions associated with Trogarzo. However, maintaining a balanced diet and staying well-hydrated are generally recommended for overall health and to support immune function.

What should I do if I forget a dose?

If you miss a dose of Trogarzo, contact your healthcare provider or clinic as soon as possible to reschedule your infusion appointment. It’s important not to double the dose to make up for a missed one.

Consistency in receiving Trogarzo infusions according to the prescribed schedule is crucial for its effectiveness in managing HIV infection. Missing doses or delaying treatment may impact the control of the virus and could potentially lead to treatment failure or the development of drug resistance.

What side effects can this medication cause?

Trogarzo (ibalizumab-uiyk) can cause various side effects, although not everyone will experience them. Some common side effects associated with Trogarzo include:

• Diarrhea
• Dizziness
• Nausea
• Rash
• Headache
• Fatigue
• Upper respiratory tract infection
• Cough
• Pyrexia (fever)
• Depression

These side effects are generally mild to moderate in severity and may improve over time as your body adjusts to the medication. However, if any of these side effects persist or worsen, it’s essential to notify your healthcare provider.

In addition to these common side effects, Trogarzo may also cause more serious adverse reactions in some individuals. These can include:

• Hypersensitivity reactions: Symptoms may include rash, itching, swelling, difficulty breathing, or severe dizziness. Seek immediate medical attention if you experience any signs of a hypersensitivity reaction.
• Immune reconstitution inflammatory syndrome (IRIS): Patients with advanced HIV infection may experience worsening of pre-existing infections or the development of new infections after starting Trogarzo therapy. Symptoms may include fever, swollen lymph nodes, and worsening symptoms of opportunistic infections. Notify your healthcare provider if you experience any signs of IRIS.
• Other adverse events: Trogarzo may also be associated with other rare but potentially serious side effects. These can include liver problems, kidney problems, and changes in body fat distribution (lipodystrophy). Notify your healthcare provider if you experience any new or unusual symptoms while taking Trogarzo.

It’s essential to communicate openly with your healthcare provider about any side effects or concerns you may have while taking Trogarzo. They can provide guidance on managing side effects and determine if any adjustments to your treatment regimen are necessary. Additionally, seek medical attention promptly if you experience any signs of a severe allergic reaction or other serious adverse events.

What should I know about storage and disposal of this medication?

Storage and Disposal:

• Storage: Trogarzo should be stored according to the manufacturer’s instructions, typically at room temperature away from light and moisture. It should be kept in its original packaging until ready for use.
• Disposal: Unused or expired Trogarzo should be disposed of properly according to local regulations. Do not dispose of Trogarzo in household trash or flush it down the toilet unless instructed to do so. Contact your healthcare provider, pharmacist, or local waste disposal authority for guidance on proper disposal methods.

In case of emergency/overdose

In case of emergency or overdose with Trogarzo, seek immediate medical attention or contact your local poison control center. It’s essential to provide as much information as possible about the medication and the circumstances of the overdose.

What other information should I know?

• Follow-Up: Attend all scheduled appointments with your healthcare provider for Trogarzo infusions and follow-up evaluations. Regular monitoring of your HIV infection and overall health is essential for effective management.
• Laboratory Tests: Your healthcare provider may perform regular laboratory tests to monitor your HIV viral load, CD4 cell count, and other parameters to assess the effectiveness of Trogarzo therapy.
• HIV Transmission: Trogarzo is not a cure for HIV infection and does not prevent the transmission of HIV to others. Practice safe sex and use appropriate precautions to reduce the risk of transmitting HIV to sexual partners or through sharing needles or other injection equipment.
• Medication Adherence: It’s important to adhere to the prescribed treatment regimen for Trogarzo and take all other prescribed HIV medications as directed. Skipping doses or discontinuing treatment without consulting your healthcare provider may lead to treatment failure or the development of drug resistance.
• Pregnancy and Breastfeeding: Inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding before starting Trogarzo therapy. The safety of Trogarzo in pregnant or breastfeeding individuals has not been established.
• Drug Interactions: Inform your healthcare provider about all medications, supplements, and herbal products you are taking, as Trogarzo may interact with certain drugs. Your healthcare provider can help manage potential drug interactions and adjust your treatment regimen as needed.

By following these guidelines and staying informed about Trogarzo therapy, you can maximize the benefits of treatment while minimizing the risk of adverse effects and complications. Always consult your healthcare provider if you have any questions or concerns about your medication regimen.